AstraZeneca rallies as results show Tagrisso slows lung cancer progression

AstraZeneca PLC (LSE:AZN) shares swung 4% higher on Monday after it emerged that blockbuster drug Tagrisso (osimertinib), with the addition of chemotherapy, has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval followed a priority review by the Food and Drug Administration (FDA) based on the results from the FLAURA2 Phase III trial published in The New England Journ ...